Nymox Pharmaceutical Company Profile (NASDAQ:NYMX)

About Nymox Pharmaceutical (NASDAQ:NYMX)

Nymox Pharmaceutical logoNymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also has a patent portfolio covering its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex conducts research and development, and manufacturing for NicAlert and TobacAlert.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Diagnostic Substances
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NYMX
  • CUSIP: N/A
  • Web: www.nymox.com
Capitalization:
  • Market Cap: $187.15 million
  • Outstanding Shares: 49,251,000
Average Prices:
  • 50 Day Moving Avg: $4.22
  • 200 Day Moving Avg: $3.46
  • 52 Week Range: $1.62 - $5.79
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.67
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $283,611.00
  • Price / Sales: 659.90
  • Book Value: ($0.01) per share
  • Price / Book: -380.00
Profitability:
  • EBIDTA: ($12,870,000.00)
  • Net Margins: -4,510.97%
  • Return on Assets: -1,522.75%
Debt:
  • Debt-to-Equity Ratio: -0.63%
  • Current Ratio: 0.92%
  • Quick Ratio: 0.91%
Misc:
  • Average Volume: 229,965 shs.
  • Beta: 0.77
  • Short Ratio: 10.15
 

Frequently Asked Questions for Nymox Pharmaceutical (NASDAQ:NYMX)

What is Nymox Pharmaceutical's stock symbol?

Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."

How were Nymox Pharmaceutical's earnings last quarter?

Nymox Pharmaceutical Co. (NASDAQ:NYMX) released its earnings results on Friday, November, 14th. The company reported ($0.02) earnings per share (EPS) for the quarter. The business had revenue of $0.08 million for the quarter. View Nymox Pharmaceutical's Earnings History.

Who are some of Nymox Pharmaceutical's key competitors?

How do I buy Nymox Pharmaceutical stock?

Shares of Nymox Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Nymox Pharmaceutical stock cost?

One share of Nymox Pharmaceutical stock can currently be purchased for approximately $3.80.

Analyst Ratings

Consensus Ratings for Nymox Pharmaceutical (NASDAQ:NYMX) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Nymox Pharmaceutical (NASDAQ:NYMX)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Nymox Pharmaceutical (NASDAQ:NYMX)
Earnings by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)
Earnings History by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2014Q314($0.02)$0.08 millionViewN/AView Earnings Details
11/13/2013Q3($0.03)ViewN/AView Earnings Details
5/15/2013Q1 2013($0.05)($0.03)$0.78 million$0.18 millionViewN/AView Earnings Details
11/14/2012Q312($0.06)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Nymox Pharmaceutical (NASDAQ:NYMX)
Current Year EPS Consensus Estimate: $-0.20 EPS
Next Year EPS Consensus Estimate: $-0.57 EPS

Dividends

Dividend History for Nymox Pharmaceutical (NASDAQ:NYMX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Nymox Pharmaceutical (NASDAQ:NYMX)
Insider Ownership Percentage: 54.00%
Institutional Ownership Percentage: 1.76%
Insider Trades by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)
Insider Trades by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/8/2017James George RobinsonDirectorBuy50,000$3.59$179,500.00View SEC Filing  
8/10/2016James George RobinsonDirectorBuy500$2.47$1,235.00View SEC Filing  
8/4/2016James George RobinsonDirectorBuy7,000$3.41$23,870.00View SEC Filing  
7/29/2016James George RobinsonDirectorBuy22,500$3.86$86,850.00View SEC Filing  
7/20/2016James George RobinsonDirectorBuy10,000$3.33$33,300.00View SEC Filing  
7/7/2016James George RobinsonDirectorBuy20,000$3.28$65,600.00View SEC Filing  
6/29/2016James George RobinsonDirectorBuy17,500$3.53$61,775.00View SEC Filing  
6/24/2016James George RobinsonDirectorBuy22,500$2.97$66,825.00View SEC Filing  
5/13/2016James George RobinsonDirectorBuy28,010$2.31$64,703.10View SEC Filing  
5/3/2016James George RobinsonDirectorBuy6,990$2.36$16,496.40View SEC Filing  
4/29/2016James George RobinsonDirectorBuy15,000$2.27$34,050.00View SEC Filing  
4/15/2016James George RobinsonDirectorBuy39,500$2.39$94,405.00View SEC Filing  
4/1/2016James George RobinsonDirectorBuy20,500$2.40$49,200.00View SEC Filing  
3/24/2016James George RobinsonDirectorBuy40,000$2.29$91,600.00View SEC Filing  
1/12/2016James George RobinsonDirectorBuy20,000$2.44$48,800.00View SEC Filing  
1/8/2016James George RobinsonDirectorBuy95,000$2.90$275,500.00View SEC Filing  
12/30/2015James George RobinsonDirectorBuy5,000$3.38$16,900.00View SEC Filing  
12/29/2015James George RobinsonDirectorBuy14,000$3.55$49,700.00View SEC Filing  
12/28/2015James George RobinsonDirectorBuy6,000$3.79$22,740.00View SEC Filing  
12/23/2015James George RobinsonDirectorBuy29,854$3.54$105,683.16View SEC Filing  
12/18/2015James George RobinsonDirectorBuy63,334$3.56$225,469.04View SEC Filing  
12/11/2015James George RobinsonDirectorBuy46,812$3.51$164,310.12View SEC Filing  
12/4/2015James George RobinsonDirectorBuy110,000$3.44$378,400.00View SEC Filing  
9/3/2015James George RobinsonDirectorBuy100,000$2.25$225,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Nymox Pharmaceutical (NASDAQ:NYMX)
Latest Headlines for Nymox Pharmaceutical (NASDAQ:NYMX)
Source:
DateHeadline
finance.yahoo.com logoNymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
finance.yahoo.com - May 24 at 10:18 AM
finance.yahoo.com logoNymox reports 1Q loss
finance.yahoo.com - May 16 at 10:05 AM
globenewswire.com logoNYMOX Files For Approval of First In Class Prostate Drug in Europe: Teleconference at 4:30 ...
globenewswire.com - May 12 at 12:29 AM
feeds.benzinga.com logoNYMOX Files For Approval of First In Class Prostate Drug in Europe: Teleconference at 4:30 EDT
feeds.benzinga.com - May 10 at 11:37 AM
finance.yahoo.com logoNYMOX Files For Approval of First In Class Prostate Drug in Europe: Company To Hold Teleconference Wednesday May 10 at 4:30 EDT
finance.yahoo.com - May 8 at 12:13 PM
americanbankingnews.com logoNymox Pharmaceutical (NYMX) Earning Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - May 4 at 12:08 PM
globenewswire.com logoNYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe - GlobeNewswire (press release)
globenewswire.com - May 3 at 8:06 PM
finance.yahoo.com logoNYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe
finance.yahoo.com - May 3 at 8:06 PM
americanbankingnews.com logoSomewhat Favorable News Coverage Likely to Affect Nymox Pharmaceutical (NYMX) Stock Price
www.americanbankingnews.com - April 23 at 10:44 PM
americanbankingnews.com logoNymox Pharmaceutical (NYMX) Earning Somewhat Favorable Media Coverage, Study Finds
www.americanbankingnews.com - April 21 at 12:33 AM
finance.yahoo.com logoNymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017
finance.yahoo.com - April 7 at 11:39 AM
finance.yahoo.com logoPacific Biosciences of California and Nymox Pharmaceutical Move Up On Bullish Product Environments
finance.yahoo.com - March 30 at 7:15 PM
americanbankingnews.com logoNymox Pharmaceutical Co. (NYMX) Director James George Robinson Purchases 50,000 Shares
www.americanbankingnews.com - March 29 at 10:34 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Vertex Pharma, Morgan Stanley, F5, Exar, Tonix Pharma, Vertex - Nasdaq
www.nasdaq.com - March 29 at 7:38 PM
finance.yahoo.com logoNymox Provides Update on Fexapotide Development
finance.yahoo.com - March 29 at 7:38 PM
finance.yahoo.com logo10:46 am Nymox Pharma provides update, says now expects to submit its initial filing seeking approval for Fexapotide Triflutate in the next few weeks
finance.yahoo.com - March 29 at 7:38 PM
finance.yahoo.com logoIMPORTANT INVESTOR NOTICE: Lundin Law PC Announces an Investigation of Nymox Pharmaceutical Corporation and Advises Investors with Losses to Contact the Firm
finance.yahoo.com - March 1 at 10:26 AM
finance.yahoo.com logoNymox Pharmaceutical Corporation Investigated For Securities Fraud By Block & Leviton After Report Reveals Pervasive Misconduct By The Company
finance.yahoo.com - March 1 at 10:26 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Nymox Pharmaceutical Corporation (NYMX)
finance.yahoo.com - March 1 at 10:26 AM
247wallst.com logo5 Biohealth Stocks Rising 10% or More on News
247wallst.com - March 1 at 10:26 AM
thestreet.com logoNymox Pharmaceuticals (NYMX) Stock Surges on Prostate Drug Progress
www.thestreet.com - March 1 at 10:26 AM
thestreet.com logoNymox Pharmaceuticals (NYMX) Stock Surges on Long-Term Prostate Drug Trial Success
www.thestreet.com - March 1 at 10:26 AM
finance.yahoo.com logoWhy Nymox Pharma (NYMX) Closed the Day Up 83%
finance.yahoo.com - March 1 at 10:26 AM
thestreet.com logoJabbing a Needle in the Overinflated Nymox Prostate Drug Hype
www.thestreet.com - March 1 at 10:26 AM
finance.yahoo.com logoNymox Wins Big on Late-Stage Trial
finance.yahoo.com - March 1 at 10:26 AM
finance.yahoo.com logoCompany News for October 12, 2016
finance.yahoo.com - March 1 at 10:26 AM
reuters.com logoProfile: Nymox Pharmaceutical Corp (NYMX.OQ)
www.reuters.com - January 28 at 7:04 PM
investorplace.com logoHottest Manufacturing Stocks Now – FOLD AQXP NLNK ACHN - Investorplace.com
investorplace.com - December 27 at 9:57 AM

Social

Chart

Nymox Pharmaceutical (NYMX) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff